Oncotelic <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Launches AI Platform to Accelerate TGF-β Research
Oncotelic Therapeutics Inc. has announced the launch of PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful insights from large-scale biomedical datasets without the need to train bespoke large language models. Alongside this, the company has opened access to its comprehensive TGF-β literature corpus, which includes more than 125,000 PubMed abstracts, via a dedicated Discord research channel. The PDAOAI platform has already supported research published in peer-reviewed journals, such as the International Journal of Molecular Sciences, where it aided in synthesizing evidence on survival-associated biological axes, including TGFB2, DNMT3A, and GMPS, across various tumor microenvironment settings and patient populations. Researchers are invited to join the community for further collaboration and data exploration.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9615845-en) on December 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.